Study on the establishment of pharmaceutical care pathway for tumor patients undergoing chemotherapy and its effect on cancer-induced fatigue

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050956

Enrollment

Unknown

Registered

2021-09-08

Start date

2018-07-01

Completion date

Unknown

Last updated

2022-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung neoplasm

Interventions

intervention group:Clinical pharmaceutical pathway

control group:Nil

Eligibility

Sex/Gender

All

Age

41 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18~70 years; 2. Pathological diagnosis as lung cancer with the need of chemotherapy; 3. The patient is hospitalized with chemotherapy for no more than 3 weeks; 4. (PS) score = 6 months; 5. Experienced non-specific fatigue, weakness, systemic decline, lethargy and other symptoms; 6. Having the health-conscious and ability of language communication.

Exclusion criteria

Exclusion criteria: 1. Patients with severe intellectual or cognitive dysfunction; 2. Suffering from mental illness, or combined with serious heart disease, liver and kidney dysfunction or other infectious diseases; 3. Other discomforts were included in the study.

Design outcomes

Primary

Measure	Time frame
Cancer relate fatigue;	—

Secondary

Measure	Time frame
negative emotion;quality of life;	—

Countries

China

Contacts

Public ContactXu Xiangwei

Yongkang Frist People's Hospital

xu15858830343@126.com+86 15858830343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026